| Dr Nicholas George Dyc, MD | |
|
16001 W 9 Mile Rd, Dept. Of Emergency Medicine, Southfield, MI 48075-4818 | |
| (248) 849-3015 | |
| Not Available |
| Full Name | Dr Nicholas George Dyc |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 16 Years |
| Location | 16001 W 9 Mile Rd, Southfield, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184860272 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 4301092600 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Henry Ford Allegiance Health | Jackson, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Independent Observation Physicians Pllc | 3577603604 | 74 |
| Independent Emergency Physicians, P.c. | 6709798325 | 43 |
News Archive
UBM Medica's announced today that ConsultantLive now features special coverage focused on helping clinicians diagnose and control migraine headaches.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
BrainStorm Cell Therapeutics Inc., a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journal Neurology.
There is constant pressure in the healthcare industry to streamline patient care delivery systems that will function effectively under the real world constraints faced by public and private hospitals. Whether it is an admissions process, patient records or a doctor's office environment, Visioneer scanners make short and easy work out of converting paper into digital documents.
› Verified 2 days ago
| Entity Name | Independent Emergency Physicians, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780791343 PECOS PAC ID: 6709798325 Enrollment ID: O20031103000407 |
News Archive
UBM Medica's announced today that ConsultantLive now features special coverage focused on helping clinicians diagnose and control migraine headaches.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
BrainStorm Cell Therapeutics Inc., a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journal Neurology.
There is constant pressure in the healthcare industry to streamline patient care delivery systems that will function effectively under the real world constraints faced by public and private hospitals. Whether it is an admissions process, patient records or a doctor's office environment, Visioneer scanners make short and easy work out of converting paper into digital documents.
› Verified 2 days ago
| Entity Name | Independent Observation Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700119500 PECOS PAC ID: 3577603604 Enrollment ID: O20091221000327 |
News Archive
UBM Medica's announced today that ConsultantLive now features special coverage focused on helping clinicians diagnose and control migraine headaches.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
BrainStorm Cell Therapeutics Inc., a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journal Neurology.
There is constant pressure in the healthcare industry to streamline patient care delivery systems that will function effectively under the real world constraints faced by public and private hospitals. Whether it is an admissions process, patient records or a doctor's office environment, Visioneer scanners make short and easy work out of converting paper into digital documents.
› Verified 2 days ago
| Entity Name | Iep Urgent Care - Jackson Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336725688 PECOS PAC ID: 0042619132 Enrollment ID: O20210521001112 |
News Archive
UBM Medica's announced today that ConsultantLive now features special coverage focused on helping clinicians diagnose and control migraine headaches.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
BrainStorm Cell Therapeutics Inc., a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journal Neurology.
There is constant pressure in the healthcare industry to streamline patient care delivery systems that will function effectively under the real world constraints faced by public and private hospitals. Whether it is an admissions process, patient records or a doctor's office environment, Visioneer scanners make short and easy work out of converting paper into digital documents.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nicholas George Dyc, MD Po Box 100, Dept. Of Emergency Medicine, Royal Oak, MI 48068-0100 Ph: (248) 849-3015 | Dr Nicholas George Dyc, MD 16001 W 9 Mile Rd, Dept. Of Emergency Medicine, Southfield, MI 48075-4818 Ph: (248) 849-3015 |
News Archive
UBM Medica's announced today that ConsultantLive now features special coverage focused on helping clinicians diagnose and control migraine headaches.
Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes.
BrainStorm Cell Therapeutics Inc., a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journal Neurology.
There is constant pressure in the healthcare industry to streamline patient care delivery systems that will function effectively under the real world constraints faced by public and private hospitals. Whether it is an admissions process, patient records or a doctor's office environment, Visioneer scanners make short and easy work out of converting paper into digital documents.
› Verified 2 days ago
Dr. Lindsay Anne Richmond-pruneau, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 16001 W 9 Mile Rd, Southfield, MI 48075 Phone: 248-849-3000 | |
Dr. James Bishop Jr., M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 16001 W 9 Mile Rd, Southfield, MI 48075 Phone: 248-849-3000 | |
Dr. Howard Fertel, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 16001 W 9 Mile Rd, Southfield, MI 48075 Phone: 248-849-3000 | |
Dr. Ann Marsh-senic, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 16001 W 9 Mile Rd, Southfield, MI 48075 Phone: 248-849-3000 | |
Dr. Gary Pilchak, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 16001 W 9 Mile Rd, Southfield, MI 48075 Phone: 248-849-3000 | |
Dr. Nirmal Nandakumar, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 16001 W 9 Mile Rd, Southfield, MI 48075 Phone: 248-849-3000 | |
Andrew Solway, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 16001 W 9 Mile Rd, Southfield, MI 48075 Phone: 248-849-2407 |